OLD Mutual Customised Solutions Proprietary Ltd. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,971 shares of the biopharmaceutical company’s stock after purchasing an additional 1,800 shares during the period. OLD Mutual Customised Solutions Proprietary Ltd.’s holdings in Gilead Sciences were worth $5,311,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. DnB Asset Management AS increased its position in shares of Gilead Sciences by 4.4% in the second quarter. DnB Asset Management AS now owns 156,552 shares of the biopharmaceutical company’s stock valued at $11,090,000 after acquiring an additional 6,600 shares during the period. Gamco Investors INC. ET AL lifted its stake in shares of Gilead Sciences by 15.4% in the second quarter. Gamco Investors INC. ET AL now owns 14,980 shares of the biopharmaceutical company’s stock worth $1,061,000 after buying an additional 2,000 shares in the last quarter. Highstreet Asset Management Inc. lifted its stake in shares of Gilead Sciences by 13.0% in the second quarter. Highstreet Asset Management Inc. now owns 48,756 shares of the biopharmaceutical company’s stock worth $3,454,000 after buying an additional 5,621 shares in the last quarter. Vishria Bird Financial Group LLC bought a new position in shares of Gilead Sciences in the second quarter worth approximately $4,307,000. Finally, Intrust Bank NA lifted its stake in shares of Gilead Sciences by 10.0% in the second quarter. Intrust Bank NA now owns 20,327 shares of the biopharmaceutical company’s stock worth $1,440,000 after buying an additional 1,849 shares in the last quarter. 77.99% of the stock is owned by institutional investors and hedge funds.

A number of brokerages recently weighed in on GILD. BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Monday, August 20th. Mizuho set a $94.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, July 31st. Zacks Investment Research cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 25th. Finally, Robert W. Baird cut shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 target price for the company. in a report on Thursday, July 26th. Twelve equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Buy” and an average target price of $88.24.

GILD stock traded down $0.32 during trading on Friday, hitting $76.24. 6,083,267 shares of the company’s stock traded hands, compared to its average volume of 7,359,248. Gilead Sciences, Inc. has a 52 week low of $64.27 and a 52 week high of $89.54. The company has a quick ratio of 2.92, a current ratio of 3.00 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $100.09 billion, a P/E ratio of 8.91, a price-to-earnings-growth ratio of -3.92 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The business had revenue of $5.65 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same quarter last year, the business earned $2.56 earnings per share. Gilead Sciences’s quarterly revenue was down 20.9% compared to the same quarter last year. As a group, analysts anticipate that Gilead Sciences, Inc. will post 6.56 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 27th. Stockholders of record on Friday, September 14th were issued a $0.57 dividend. The ex-dividend date of this dividend was Thursday, September 13th. This represents a $2.28 annualized dividend and a dividend yield of 2.99%. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.

In other news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $78.04, for a total value of $3,902,000.00. Following the completion of the sale, the director now owns 3,067,762 shares in the company, valued at approximately $239,408,146.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 150,000 shares of company stock valued at $11,502,500 in the last 90 days. Company insiders own 1.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Further Reading: Marijuana Stocks Future Looks Bright

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.